Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy DURECT Corporation stock | $1.98

Own DURECT Corporation stock in just a few minutes.

Fact checked

DURECT Corporation is a drug manufacturers-specialty & generic business based in the US. DURECT Corporation shares (DRRX) are listed on the NASDAQ and all prices are listed in US Dollars. DURECT Corporation employs 95 staff and has a trailing 12-month revenue of around USD$42 million.

How to buy shares in DURECT Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for DURECT Corporation. Find the stock by name or ticker symbol: DRRX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until DURECT Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$1.98, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of DURECT Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of DURECT Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

DURECT Corporation share price

Use our graph to track the performance of DRRX stocks over time.

DURECT Corporation shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$1.98
52-week rangeUSD$0.9502 - USD$3.949
50-day moving average USD$1.9285
200-day moving average USD$1.9974
Wall St. target priceUSD$6.17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.151

Buy DURECT Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy DURECT Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

DURECT Corporation price performance over time

Historical closes compared with the close of $1.98 from 2020-12-09

1 week (2021-01-12) -6.60%
1 month (2020-12-18) -13.54%
3 months (2020-10-19) 9.39%
6 months (2020-07-17) -9.59%
1 year (2020-01-17) -21.12%
2 years (2019-01-18) 241.38%
3 years (2018-01-19) 65.00%
5 years (2016-01-19) 69.23%

DURECT Corporation financials

Revenue TTM USD$42 million
Gross profit TTM USD$-5,288,000
Return on assets TTM -6.07%
Return on equity TTM -32.35%
Profit margin -21.85%
Book value $0.171
Market capitalisation USD$436.8 million

TTM: trailing 12 months

Shorting DURECT Corporation shares

There are currently 8.8 million DURECT Corporation shares held short by investors – that's known as DURECT Corporation's "short interest". This figure is 4.4% down from 9.2 million last month.

There are a few different ways that this level of interest in shorting DURECT Corporation shares can be evaluated.

DURECT Corporation's "short interest ratio" (SIR)

DURECT Corporation's "short interest ratio" (SIR) is the quantity of DURECT Corporation shares currently shorted divided by the average quantity of DURECT Corporation shares traded daily (recently around 766742.58456201). DURECT Corporation's SIR currently stands at 11.53. In other words for every 100,000 DURECT Corporation shares traded daily on the market, roughly 11530 shares are currently held short.

However DURECT Corporation's short interest can also be evaluated against the total number of DURECT Corporation shares, or, against the total number of tradable DURECT Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case DURECT Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 DURECT Corporation shares in existence, roughly 40 shares are currently held short) or 0.0499% of the tradable shares (for every 100,000 tradable DURECT Corporation shares, roughly 50 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against DURECT Corporation.

Find out more about how you can short DURECT Corporation stock.

DURECT Corporation share dividends

We're not expecting DURECT Corporation to pay a dividend over the next 12 months.

DURECT Corporation share price volatility

Over the last 12 months, DURECT Corporation's shares have ranged in value from as little as $0.9502 up to $3.949. A popular way to gauge a stock's volatility is its "beta".

DRRX.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while DURECT Corporation's is 1.7575. This would suggest that DURECT Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

DURECT Corporation overview

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; Gilead Sciences, Inc; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site